MAPAX
Price
$34.97
Change
+$0.12 (+0.34%)
Updated
Jul 31 closing price
Net Assets
902.54M
RMEBX
Price
$64.44
Change
+$0.03 (+0.05%)
Updated
Jul 31 closing price
Net Assets
118.05B
Interact to see
Advertisement

MAPAX vs RMEBX

MAPAX vs RMEBX Comparison Chart in %
View a ticker or compare two or three
VS
MAPAX vs. RMEBX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MAPAX is a StrongBuy and RMEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 118B vs. MAPAX (903M). MAPAX pays higher dividends than RMEBX: MAPAX (1.21) vs RMEBX (0.99). MAPAX was incepted earlier than RMEBX: MAPAX (27 years) vs RMEBX (12 years). RMEBX (1.07) and MAPAX (1.02) have similar cost to investors . MAPAX is a more actively managed with annual turnover of: 43.00 vs. RMEBX (30.00). RMEBX has a lower initial minimum investment than MAPAX: RMEBX (250) vs MAPAX (15000). MAPAX annual gain was more profitable for investors over the last year : 15.27 vs. RMEBX (8.96). RMEBX return over 5 years is better than : 36.13 vs. MAPAX (-29.96).
MAPAXRMEBXMAPAX / RMEBX
Total Expense Ratio1.021.0795%
Annual Report Gross Expense Ratio1.021.0795%
Fund Existence27 years12 years-
Gain YTD12.4809.416133%
Front Load6%N/A-
Min. Initial Investment150002506,000%
Min. Initial Investment IRAN/AN/A-
Net Assets903M118B1%
Annual Yield % from dividends1.210.99122%
Returns for 1 year15.278.96171%
Returns for 3 years27.7032.6385%
Returns for 5 years-29.9636.13-83%
Returns for 10 years3.6090.644%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEOTX15.100.17
+1.14%
Voya Large Cap Growth Port S2
JRAAX88.86N/A
N/A
Janus Henderson Research A
VLLIX45.39-0.03
-0.07%
Value Line Larger Companies Focus Instl
BHCFX21.68-0.10
-0.46%
Baron Health Care Retail
FBDIX193.96-3.99
-2.02%
Franklin Biotechnology Discovery A